Takeda Grows Immuno-Oncology Portfolio With $525m Maverick Acquisition
Japanese Pharma Exercises Option Under 2017 Deal
Takeda has exercised its option to acquire Maverick Therapeutics for $525m, expanding its IO development business. • Source: Shutterstock 
